Class Action Lawsuit Filed Against Tenax Therapeutics Amidst Securities Violations

Pomerantz Law Firm Takes Action Against Tenax Therapeutics

In a significant legal move, Pomerantz LLP has initiated a class action lawsuit against Tenax Therapeutics, Inc. (NASDAQ: TENX) and several of its top officials, targeting the period between November 13, 2023 and August 7, 2026. This lawsuit has been filed in the United States District Court for the Middle District of North Carolina and is identified under docket number 26-cv-01624.

The lawsuit aims to represent a class of individuals and entities, excluding the defendants, who purchased or acquired Tenax's securities during the aforementioned period. The plaintiffs are seeking damages for the alleged violations of federal securities laws and are pursuing remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5.

The class action was prompted by what the plaintiffs allege were materially false and misleading statements made by Tenax officials regarding the company's business practices, operations, and future prospects. Specifically, the complaint asserts that during the class period, Tenax misrepresented the effectiveness of its key product, TNX-103, a novel cardiopulmonary therapy that was undergoing crucial clinical trials.

Prior to the class period, Tenax had conducted and completed a Phase 2 study of levosimendan (TNX-103). The results were touted to show significant improvements in patient outcomes related to pulmonary hypertension with heart failure, a condition with limited treatment options. However, the lawsuit contends that as the clinical trials progressed, Defendants overstated the prospects and effectiveness of TNX-103.

It was only on August 10, 2026, that the reality began to surface when Tenax released its Phase 3 LEVEL trial results, indicating that the drug did not meet its primary endpoint of improving patient performance in a six-minute walk test compared to a placebo nor did it fulfill the key secondary endpoint concerning symptom reduction. Following this release, Tenax's share price plummeted approximately $12.06, equating to a staggering 89.77% drop.

This drastic decline triggered further concerns and questions regarding the integrity of the information provided by Tenax’s executives. Many investors felt misled and have now joined the class action to seek redress under the law.

Pomerantz LLP, known for its prowess in handling class action lawsuits, particularly surrounding securities fraud, underscored its commitment to advocating for affected investors. Those who purchased or acquired Tenax securities during the specified class period have until December 28, 2026, to apply for the opportunity to serve as Lead Plaintiff.

Investors interested in obtaining a copy of the complaint or exploring their options can access resources at Pomerantz's official website, or reach out to Danielle Peyton of Pomerantz LLP directly for personalized assistance. It's advisable for interested parties to provide their contact details, including mailing addresses and phone numbers, as well as information about the number of Tenax shares acquired during the class period when they reach out for assistance.

Pomerantz LLP, reflecting on its history spanning over 85 years, remains a dedicated force in protecting the rights of investors impacted by securities fraud and corporate misconduct. The firm was founded by the late Abraham L. Pomerantz, a predecessor in the field of class action bar, and has worked tirelessly to recover billions in damages for countless victims of such misconduct. Their long-standing reputation underscores the critical importance of investor protection in today's financial landscape.

For those affected by this lawsuit or who want more information about joining the class action, resources are available online or through direct contact with Pomerantz LLP’s seasoned attorneys.

Disclaimer: This article does not constitute legal advice and should not be considered as such. It is always recommended to seek advice from a qualified legal professional for any legal matters.